Skip to main content
Erschienen in: World Journal of Urology 1/2009

01.02.2009 | Topic Paper

Outcomes of patients with clinical CIS-only disease treated with radical cystectomy

verfasst von: George Jiunruey Huang, Philip H. Kim, Donald G. Skinner, John P. Stein

Erschienen in: World Journal of Urology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To report the long-term oncological efficacy of radical cystectomy for patients with presumed clinical CIS only disease, to characterize the likelihood of clinical understaging, and to characterize the pattern of recurrence.

Methods

One thousand six hundred patients have undergone radical cystectomy and pelvic lymph node dissection with intent to cure from August 1971 to December 2005 at the University of Southern California; 27 patients from this cohort who satisfied both the inclusion and exclusion criteria were identified. Relevant clinical and pathological data at time of cystectomy and during follow-up were reported. Overall and recurrence-free survival was estimated using the Kaplan–Meier method.

Results

At time of cystectomy, 33% of patients were found to be clinically understaged. Median follow-up was 94 months. Estimated 5- and 10-year overall survival was 87 and 56%, respectively. Estimated 5- and 10-year recurrence-free survival was 100 and 83%, respectively.

Conclusions

Excellent long-term survival outcomes can be achieved with radical cystectomy. Radical cystectomy should be strongly considered for patients who have failed prior intravesical therapy. Long-term surveillance of the retained urethra and of the upper tract is essential, as recurrence can occur years following cystectomy. Patients who recur are at high risk of dying from disease.
Literatur
1.
Zurück zum Zitat Lamm DL (1992) Carcinoma in situ. Urol Clin North Am 19:499–508PubMed Lamm DL (1992) Carcinoma in situ. Urol Clin North Am 19:499–508PubMed
2.
Zurück zum Zitat Wolf H, Melsen F, Pedersen SE, Nielsen KT (1994) Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 157:147–151PubMed Wolf H, Melsen F, Pedersen SE, Nielsen KT (1994) Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 157:147–151PubMed
4.
Zurück zum Zitat Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970. doi:10.1016/S0022-5347(05)64273-5 Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970. doi:10.​1016/​S0022-5347(05)64273-5
10.
Zurück zum Zitat Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 19:666–675PubMed Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 19:666–675PubMed
11.
Zurück zum Zitat Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59. doi:10.1016/j.eururo.2005.03.021 (discussion 59)PubMedCrossRef Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59. doi:10.​1016/​j.​eururo.​2005.​03.​021 (discussion 59)PubMedCrossRef
12.
13.
Zurück zum Zitat Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM (1992) Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 147:92–95PubMed Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM (1992) Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 147:92–95PubMed
16.
Zurück zum Zitat Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP (2007) Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1, 069 patients with 10-year followup. J Urol 177:2088–2094. doi:10.1016/j.juro.2007.01.133 PubMedCrossRef Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP (2007) Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1, 069 patients with 10-year followup. J Urol 177:2088–2094. doi:10.​1016/​j.​juro.​2007.​01.​133 PubMedCrossRef
17.
Zurück zum Zitat Tran W, Serio AM, Raj GV, Dalbagni G, Vickers AJ, Bochner BH, Herr H, Donat SM (2008) Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol 179:96–100. doi:10.1016/j.juro.2007.08.131 PubMedCrossRef Tran W, Serio AM, Raj GV, Dalbagni G, Vickers AJ, Bochner BH, Herr H, Donat SM (2008) Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol 179:96–100. doi:10.​1016/​j.​juro.​2007.​08.​131 PubMedCrossRef
Metadaten
Titel
Outcomes of patients with clinical CIS-only disease treated with radical cystectomy
verfasst von
George Jiunruey Huang
Philip H. Kim
Donald G. Skinner
John P. Stein
Publikationsdatum
01.02.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0344-2

Weitere Artikel der Ausgabe 1/2009

World Journal of Urology 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.